Integration of Molecular and Biological Abnormalities in Quest for Selective Treatment of Chronic Myelogenous Leukemia (CML)

References

• Fefer A., Thomas E. D. Bone marrow transplantation for chronic myelogenous leukemia. Chronic Myelogenous Leukemia—Molecular Approaches to Research and Therapy, A. B. Deisseroth, R. B. Arlinghaus. Marcel Dekker, Inc., New York 1991; 417–454
   Google Scholar
• Kantarjian H., Talpaz M. Treatment of chronic myelogenous leukemia. Therapy of Hematopoietic Neoplasia, E. J. Freireich, H. Kantarjian. Marcel Dekker, Inc., New York 1991; 4–174
   Google Scholar
• Wagner J. F., Zahurak M., Piantadosi S., Geller R. G., Vogelsang G. B., Wingard J. R., Saral R., Griffin C., Shah N., Zehnbauer B. A., Ambinder R., Bums W., Jones R., Stratford, May W., Rowley S., Yeager A., Santos G. W. Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: Evaluation of risks and benefits. J. Clin. Oncol. 1992; 10: 779–789
   PubMed Web of Science ®Google Scholar
• Abstracts of the 2nd International Conference on Chronic Myeloid Leukemia, Institute of Hematology, University of Bologna, Italy, October 4–8, 1992, S. Tura, M. Baccarani, B. Clarkson, R. P. Gale, M. Gobbi, J. M. Goldman, E. Mandelli, M. Talpaz. Societa Editrice Esculapio, BolognaItaly 1992
   Google Scholar
• Clarkson B. Editorial: Chronic myelogenous leukemia: Is aggressive treatment indicated. J. Clin. Oncol. 1985; 3: 135–139
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H., Kruzrock R., Trujillo J. M., Gutterman J. U. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Phil-adelphia chromosome-positive patients. Ann. Intern. Med. 1991; 114: 532–538
   PubMed Web of Science ®Google Scholar
• Tura S. Alpha-interferon treatment of chronic my-eloid leukemia (CML). Results of the Italian Cooperative Study Group on CML. Abstracts of the 2nd International Conference on Chronic Myeloid Leukemia, Institute of Hematology, University of Bologna, Italy, October 4–8, 1992, S. Tura, M. Baccarani, B. Clarkson, R. P. Gale, M. Gobbi, J. M. Goldman, F. Mandelli, M. Talpaz. Societa Editrice Esculapio, Bologna
   Google Scholar
• Ozer H., George S., Pettenati M., Wurster-Hill D., Arthur D., Rao K., Powell B., Gottlieb A., Peterson B., Rai K., Schiffer C., Bloomfietd C. D. (Abstract) Subcutaneous a-interferon (aIFN) in untreated chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML): No evidence for significant improvement in response duration or survival (CALGB 8583). Blood 1992; 80(Suppl. 1)358a, #1422
   Google Scholar
• Kluin-Nelemans J. C., Louwagie A., Delannoy A., Burgh J. F.V.D., Boogaerts M. A., Doyen C., Michaux J. L., Hagemeijer A., Van den Berghe A. H. CML treated by interferon alfa-2B vs hydroxyurea alone: Preliminary report of a large multicenter randomized trial. Blood, 80(Suppl. l)358a, for the Benelux, CML Study Group 1992(Abstract) #1423
   Google Scholar
• Lee M.S., Kantarjian H., Talpaz M., Freireich E. J., Deisseroth A., Trujillo J. M., Stass S. A. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood 1992; 79: 1920–1923
   PubMed Web of Science ®Google Scholar
• Clarkson B., Strife A. Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment. Leukemia 1993, (in press)
   PubMed Web of Science ®Google Scholar
• Strife A., Clarkson B. Biology of chronic myelogenous leukemia: Is discordant maturation the primary defect. Semin. Hematol. 1988; 25: 1–19
   PubMed Web of Science ®Google Scholar
• Clarkson B., Strife A. Discordant maturation in chronic myelogenous leukemia. Chronic Myelogenous Leukemia—Molecular Approaches to Research and Therapy, A. B. Deisseroth, R. B. Arlinghaus. Marcel Dekker, Inc., New York 1991; 3–90
   Google Scholar
• Strife A., Perez A., Lambek C., Wisniewski D., Bruno S., Darzynkiewicz Z., Clarkson B. Characterization of lineage-negative blast subpopulations derived from normal and chronic myelogenous leukemia bone marrows and determination of their responsiveness to human c-kit ligand. Cancer Res. 1993; 53: 401–409
   PubMed Web of Science ®Google Scholar
• Fokas A. S., Keller J. B., Clarkson B. D. Mathematical model of granulocytopoiesis and chronic myelogenous leukemia. Cancer Res. 1991; 51: 2084–2091
   PubMed Web of Science ®Google Scholar
• Berman E., Strife A., Wisniewski D., Desai S., Gulati S., Jhanwar S., Clarkson B. D. Duration of the preclinical phase of chronic myelogenous leukemia: A case report. Blood 1991; 78: 2969–2972
   PubMed Web of Science ®Google Scholar
• Clarkson B., Strife A. Cytokinetic considerations relevant to development of a successful therapeutic strategy in chronic myelogenous leukemia (CML). Leukemia and Lymphoma 1993, (in press)
   Web of Science ®Google Scholar
• Ogawa M., Fried J., Sakai Y., Strife A., Clarkson B. D. Studies of cellular proliferation in human leukemia. VI. The proliferative activity, generation time, and emergence time of neutrophilic granulocytes in chronic granulocytic leukemia. Cancer 1970; 25: 1031–1049
   PubMed Web of Science ®Google Scholar
• Strife A., Lambek C., Wisniewski D., Arlin Z., Thaler H., Clarkson B. Proliferative potential of subpopulations of granulocyte-macrophage progenitor cells in normal subjects and chronic myelogenous leukemia patients. Blood 1983; 62: 389–397
   PubMed Web of Science ®Google Scholar
• Strife A., Lambek C., Wisniewski D., Gulati S., Gasson J. C., Golde D. W., Welte K., Gabrilove J. L., Clarkson B. Activities of four purified growth factors on highly enriched human hematopoietic progenitor cells. Blood 1987; 69: 1508–1523
   PubMed Web of Science ®Google Scholar
• Strife A., Lambek C., Wisniewski D., Wachter M., Gulati S. C., Clarkson B. D. Discordant maturation as the primary biological defect in chronic myelogenous leukemia. Cancer, Res. 1988; 48: 1035–1041
   PubMed Web of Science ®Google Scholar
• Strife A., Lambek C., Perez A. M., Darzynkiewicz Z., Skierski J., Gulati S., Haley J., ten Dijke J., Iwata K., Clarkson B. D. The effects of transforming growth factor β3 on the growth of highly enriched hematopoietic progenitor cells derived from normal human bone marrow and peripheral blood. Cancer Res. 1991; 51: 4828–4836
   PubMed Web of Science ®Google Scholar
• Wisniewski D., Strife A., Clarkson B. Codetection of chimeric BCR/ABL (target) and β-actin (control) messenger RNA in individual CFU-GM colonies derived from CML patients using the polymerase chain reaction. Leuk. Res. 1991; 15: 867–874
   PubMed Web of Science ®Google Scholar
• Clarkson B. D., Sakai Y., Kimura T., Ohkita T., Fried J. Studies of cellular proliferation in human leukemia. II. Variability in rates of growth and cellular differentiation in acute myelomonoblastic leukemia and effects of treatment. The Proliferation and Spread of Neoplastic Cells: Proceedings of the Twenty-first Annual Symposium on Fundamental Cancer Research. 1967. The University of Texas, M. D. Anderson Hospital and Tumor Institute at Houston, Houston, 295–334
   Google Scholar
• Clarkson B. D. Review of recent studies of cellular proliferation in acute leukemia. Human Tumor Cell Kinetics, S. Perry. National Cancer Institute, Bethesda, Maryland 1969; 81–120, Monograph #30/584
   Google Scholar
• Clarkson B., Fried J., Strife A., Sakai Y., Ota K., Ohkita T. Studies of cellular proliferation in human leukemia. III. Behavior of leukemic cells in three adults with acute leukemia given continuous infusions of 3H-Thymidine for 8 or 10 days. Cancer 1970; 25: 1237–1260
   PubMed Web of Science ®Google Scholar
• Clarkson B., Strife A., Fried J., Sakai Y., Ota K., Ohkita T., Masuda R. Studies of cellular proliferation in human leukemia. IV. Behavior of normal hematopoietic cells in 3 adults with acute leukemia given continuous infusions of 3H-thymidine for 8 or 10 days. Cancer 1970; 26: 1–19
   PubMed Web of Science ®Google Scholar
• Strife A., Perez A., Lambek C., Wisniewski D., Bruno S., Darzynkiewicz Z., Clarkson B. Differences in the composition and in the efficiency of red cell production of normal and CML erythroid progenitor populations are highlighted by response to human c-kit ligand. Leuk. Res. 1993, revised manuscript resubmitted in press
   PubMed Web of Science ®Google Scholar
• Boll I., Kuhn A. Granulocytopoiesis in human bone marrow culture studies by means of kinematography. Blood 1965; 26: 449–470
   PubMed Web of Science ®Google Scholar
• Eaves A. C., Eaves C. J. Abnormalities in the erythroid progenitor compartments in patients with chronic myelogenous leukemia (CML). Exp. Hematol. 1979; 7: 65–75
   PubMed Web of Science ®Google Scholar
• Singer J. W., Adamson J. W., Arlin Z. A., Kempin S. J., Clarkson B. D., Fialkow P. J. Chronic myelogenous leukemia: In vitro studies of hematopoietic regulation in a patient undergoing intensive chemotherapy. J. Clin. Invest. 1981; 67: 1593–1598
   PubMed Web of Science ®Google Scholar
• Wognum A. W., Krystal G., Eaves C. J., Eaves A. C., Lansdorp P. M. Increased erythropoietin-receptor expression on CD34–positive bone marrow cells from patients with chronic myeloid leukemia. Blood 1992; 79: 642–649
   PubMed Web of Science ®Google Scholar